Vifor Pharma is committed to the highest standards of clinical research. Our international clinical research program spans multiple areas of medicine and is conducted in compliance with the ethical principals outlined in ICH-GCP.
Iron Replacement Therapies
The ongoing generation of scientific evidence supporting the use of Ferinject® is a top priority for Vifor Pharma. We are continually evaluating and optimising the treatment of iron deficiency with Ferinject®, Venofer® and Maltofer® in all therapeutic areas. Trials with Ferinject® in chronic kidney disease, oncology (anaemia in cancer patients), gastroenterology (inflammatory bowel diseases), surgery (pre-operative anaemia), chronic heart failure, and gynaecology have been conducted or are underway.Through additional studies Vifor Pharma will continue to further expand the scientific evidence for Ferinject®.
Velphoro® (PA21) is an iron-based, calcium-free, chewable phosphate binder. It is used for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing dialysis. In 2013, Velphoro® received US FDA approval for the treatment of hyperphosphatemia in Chronic Kidney Disease Patients on dialysis.
In our Infectious Diseases / OTX franchise we are running a comprehensive clinical program concentrating on two of our products. The safety and efficacy of Broncho-Vaxom® is being investigated in respiratory tract infections in children and in chronic obstructive pulmonary disease in adults.
The studies currently being conducted with Uro-Vaxom® are investigating the effects on recurrent urinary tract infections.
Our goal is to broaden the scientific evidence for the efficacy and safety of our products in patients suffering from infectious diseases.
Route de Moncor 10